LNTH
Lantheus Holdings, Inc.
Nasdaq In Vitro & In Vivo Diagnostic Substances Large accelerated filer

Key Financials

Operating Income
$310.8M
↓ 32.0%
Gross Profit
$942.0M
↓ 4.7%
Net Income
$233.6M
↓ 25.2%
Revenue
$1.5B
↑ 0.5%
EPS (Diluted)
$3.41
↓ 21.8%
Total Liabilities
$1.1B
↑ 27.5%
Total Assets
$2.2B
↑ 12.5%
Shareholders' Equity
$1.1B
↑ 0.2%

Recent SEC Filings

Form Type Filed Date Link
DEFA14A 8/13/2026 View on SEC
SCHEDULE 13G/A 8/13/2026 View on SEC
10-Q 8/6/2026 View on SEC
8-K 8/6/2026 View on SEC
DEFA14A 8/4/2026 View on SEC
DEFA14A 8/4/2026 View on SEC
8-K 8/4/2026 View on SEC
DEFA14A 8/3/2026 View on SEC
DEFA14A 8/3/2026 View on SEC
8-K 8/3/2026 View on SEC

Company Information

Field Value
Ticker LNTH
Company Name Lantheus Holdings, Inc.
CIK 1521036
Sector In Vitro & In Vivo Diagnostic Substances
Industry Large accelerated filer
Exchange Nasdaq
SIC Code 2835
SIC Description In Vitro & In Vivo Diagnostic Substances
Entity Type operating
Fiscal Year End 1231
State of Incorporation DE
Phone 978 671-8001